Profound Medical Corp (NAS:PROF)
$ 7.15 0.1 (1.42%) Market Cap: 209.63 Mil Enterprise Value: 188.61 Mil PE Ratio: 0 PB Ratio: 5.93 GF Score: 73/100

Profound Medical Corp at Raymond James Human Health Innovation Conference (Virtual) Transcript

Jun 22, 2021 / 02:00PM GMT
Release Date Price: $18.45 (+0.16%)
Rahul Sarugaser
Raymond James Financial, Inc. - Analyst

Good morning, everyone. Thank you so much for joining us today. My name is Rahul Sarugaser. I'm a med tech analyst with Raymond James based in the Toronto office.

I've been covering Profound Medical for the last few years. It's a company we have quite strong conviction in as it has been commercializing its device, TULSA-PRO, primarily for treatment of prostate cancer but of course broadening its utility in other prostate indications.

We have the pleasure today of Arun Menawat, Dr. Menawat, the President and CEO of the Company, who has a few opening remarks, and then we will be diving right into a fireside chat. So Arun?

Arun Menawat
Profound Medical Corp. - CEO and Chairman of the Board

Rahul, thank you so much. Thank you for inviting us, and thank you for giving me the opportunity to make the opening remarks.

I'd like to start today with a patient testimonial, and that patient happens to be me. I know my prostate has been growing for the last few years, but the PSA was

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot